Breast-Milk Iodine Concentrations and Iodine Levels of Infants According to the Iodine Status of the Country of Residence: A Systematic Review and Meta-Analysis

Thyroid ◽  
2018 ◽  
Vol 28 (1) ◽  
pp. 124-138 ◽  
Author(s):  
Pantea Nazeri ◽  
Ali Kabir ◽  
Hosein Dalili ◽  
Parvin Mirmiran ◽  
Fereidoun Azizi
Keyword(s):  
Systematic Review ◽  
Breast Milk ◽  
Meta Analysis ◽  
Iodine Status

Early versus late fortification of breast milk in preterm infants: a systematic review and meta-analysis

2020 ◽  
Vol 179 (7) ◽  
pp. 1057-1068
Author(s):  
Sriparna Basu ◽  
Jaya Upadhyay ◽  
Poonam Singh ◽  
Manish Kumar
Keyword(s):  
Systematic Review ◽  
Breast Milk ◽  
Preterm Infants ◽  
Meta Analysis

scholarly journals Effect of Domperidone on Insufficient Lactation in Puerperal Women: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

2012 ◽  
Vol 2012 ◽  
pp. 1-7 ◽  
Author(s):  
Alla Osadchy ◽  
Myla E. Moretti ◽  
Gideon Koren
Keyword(s):  
Systematic Review ◽  
Breast Milk ◽  
Randomized Controlled Trials ◽  
Milk Production ◽  
Meta Analysis ◽  
Relative Increase ◽  
Medical Community ◽  
Controlled Trials ◽  
Randomized Controlled ◽  
Breast Milk Production

Background. There is a controversy within the medical community regarding the role of domperidone as a galactagogue and the drug has been removed from the US market owing to safety concerns.Objective. To perform a systematic review and meta-analysis of the available data assessing the effect of domperidone on breast milk production in women experiencing insufficient lactation.Study Selection. Randomized controlled trials (RCTs) examining the effect of domperidone on breast milk production of puerperal women were eligible for inclusion.Data Analysis. Absolute and relative changes from baseline were calculated for individual studies and pooled using a random effects model.Results. Three RCTs including 78 participants met the inclusion criteria. All showed a statistically significant increase in breast milk production following treatment with domperidone. The analysis of pooled data demonstrated a statistically significant relative increase of 74.72% (95%  CI=54.57; 94.86,P<0.00001) in daily milk production with domperidone treatment compared to placebo. No maternal or neonatal adverse events were observed in any of the trials.Conclusions. Evidence from a few small RCTs of moderate to high quality suggests that domperidone produces a greater increase in breast milk supply than placebo.

Concentration and Prevalence of Aflatoxin M1 in Human Breast Milk in Iran: Systematic Review, Meta-Analysis, and Carcinogenic Risk Assessment: A Review

2019 ◽  
Vol 82 (5) ◽  
pp. 785-795 ◽  
Author(s):  
YADOLAH FAKHRI ◽  
RAHEB GHORBANI ◽  
MAHMOUD TAGHAVI ◽  
HASSAN KERAMATI ◽  
NAZAK AMANIDAZ ◽  
...  
Keyword(s):  
Systematic Review ◽  
Breast Milk ◽  
Meta Analysis ◽  
Hazard Index ◽  
Carcinogenic Risk ◽  
Aflatoxin M1 ◽  
Human Breast Milk ◽  
Human Breast ◽  
Male And Female ◽  
The Mean

ABSTRACTThis meta-analysis was designed to review the published reports regarding the concentration and/or prevalence of aflatoxin M1 (AFM1) in human breast milk in Iran. The carcinogenic risk for Iranian infants consuming this milk was estimated with the hazard index. The PubMed and Scopus databases and the Scientific Information Database were screened for relevant studies between 1995 and 2017, and 11 of the 112 collected studies were included in the systematic review and meta-analysis. The mean (95% confidence interval) concentration of AFM1 was 5.85 ng/L (4.54 to 7.15 ng/L), which was lower than the European Union standard (25 ng/L). The mean prevalence of AFM1 in breast milk in Iran was 42% (11 to 77%). The estimated daily intakes for male and female infants were 0.02 to 5.57 ng/kg and 0.02 to 3.68 ng/kg of body weight per day, respectively. The rank order of estimated daily intake for both male and female infants according to age was 1 week &gt; 1 month &gt; 6 months &gt; 12 months. The hazard index for all age groups of infants in all provinces in Iran was less than 1. Therefore, infants in Iran were not considered at carcinogenic risk from AFM1 in human breast milk.

scholarly journals Immune response to nucleotide-supplemented infant formulae: systematic review and meta-analysis

2007 ◽  
Vol 98 (S1) ◽  
pp. S64-S67 ◽  
Author(s):  
Pedro Gutiérrez-Castrellón ◽  
Ignacio Mora-Magaña ◽  
Luisa Díaz-García ◽  
Carlos Jiménez-Gutiérrez ◽  
Jaime Ramirez-Mayans ◽  
...  
Keyword(s):  
Systematic Review ◽  
Breast Milk ◽  
Infant Health ◽  
Respiratory Infections ◽  
Meta Analysis ◽  
Oral Polio Vaccine ◽  
Infant Formulae ◽  
Mean Differences ◽  
Dose Response Effect ◽  
Randomised Controlled

Human milk is recommended as the only alimentary source for the first six months of life. Additionally there is a medical and social need for safe and effective alternative forms of nutrition for infants who cannot be fed with breast milk. Recently the safety and efficacy of some ingredients in infant formulae, such as nucleotides have been discussed. This systematic review analyzed the available evidence to establish the efficacy, safety and dose-response effect of ribonucleotide-supplemented infant formulae (RSIFs). Randomised controlled clinical trials (RCTs) comparing RSIFs to formulae without nucleotides or breast milk were considered in this review. Outcome measures were: antibody titres to common paediatric vaccinations, total lymphocytes, lymphocyte subclasses and NK-cells, episodes of diarrhoea and acute respiratory infection. Publication quality was determined using Jadad and CONSORT guidelines. Results were combined using a random effects model and reported through standardised mean differences (WMD) or risk ratio (RR). Systematic review and meta-analysis showed that RSIFs were associated with a better antibody response to immunisation with Haemopillus influenzae vaccine [SMD 1·74 (99 %CI 1·43–2·05), P = 0·001], diphtheria toxoid [SMD 0·94 (0·75–1·12), P = 0·001], oral polio vaccine [SMD 0·73 (0·51–0·95), P = 0·001], and fewer episodes of diarrhoea [RR 0·67 (0·58–0·76), P = 0·02]. We did not find a major risk of upper respiratory infections [RR 1·11 (0·90–1·36), P = 0·50]. Available evidence suggests a positive benefit of RSFIs on infant health without any risk. These benefits begin with nucleotide addition of 1·9 mg/418·4 kJ and are maintained or increased with 10·78 mg/418·4 kJ.

Sign in / Sign up

Export Citation Format

Share Document